Mirikizumab as induction and maintenance therapy for ulcerative colitis
N Engl J Med 2023;388(26):2444–2455 doi: 10.1056/NEJMoa2207940
Mirikizumab was more effective than placebo in inducing and maintaining clinical remission in patients with moderately to severely active ulcerative colitis. D’Haens, et al. also noted that opportunistic infections and cancer developed in a small number of mirikizumab-treated patients.
Patients were enrolled in the LUCENT-1 induction study, with some continuing to the 40-week LUCENT-2 maintenance study. Primary endpoints were clinical remission at Week 12 in LUCENT-1 and at Week 40 (at 52 weeks overall) in LUCENT-2.
